real peptides FAQ

That fluctuation range is unacceptable for peptide storage. Sustained exposure to 12°C accelerates degradation significantly. Standard medical-grade refrigerators maintain 2–8°C with minimal fluctuation (±1°C), but household refrigerators often swing 3–5°C depending on door opening frequency and internal placement. Invest in a refrigerator thermometer and place reconstituted peptides in the middle or back of the unit, never in the door compartment where temperature swings are greatest. If your refrigerator regularly exceeds 8°C, peptide viability is compromised. Researchers serious about peptide integrity use dedicated laboratory refrigerators with digital temperature monitoring and alarms. The cost of replacing degraded peptides far exceeds the cost of reliable cold storage.

Contact the supplier immediately and request verification of shipping conditions and timeline. Lyophilised ipamorelin can tolerate 24–48 hours at ambient temperature during shipping with minimal degradation (3–5% potency loss), but prolonged exposure beyond 72 hours or temperatures exceeding 30°C cause significant loss. Reputable suppliers using real-time temperature loggers can confirm whether the shipment exceeded thermal thresholds. At Real Peptides, every shipment includes cold chain monitoring to verify peptides remain within specification throughout transit.

Switch to a supplier that maintains both FDA registration and third-party batch testing. Specifically HPLC purity verification and mass spectrometry identity confirmation. Request certificates of analysis (CoA) before placing an order, not after receiving product. If the supplier cannot provide CoA documentation dated within 60 days of your order, do not proceed. Real Peptides publishes batch-specific CoA documentation for every Ipamorelin product in our catalog, accessible via QR code on the product label. The documentation includes HPLC chromatograms, mass spec molecular weight confirmation, and endotoxin test results from independent ISO-accredited laboratories. For labs with active protocols that cannot tolerate supply interruptions, consider transitioning to CJC1295 Ipamorelin 5MG 5MG combination formulations, which provide both compounds in a single verified batch.

Repeat fasting IGF-1 measurement at a certified lab and verify administration technique. Non-response can result from receptor desensitization (continuous dosing without pulsatile gaps), improper reconstitution (degraded peptide due to excessive agitation or incorrect bacteriostatic water pH), or administration timing errors (too close to meals, blunting ghrelin receptor activation). Additionally, severe caloric restriction, chronic sleep deprivation, or elevated cortisol can suppress hepatic IGF-1 synthesis even when GH pulses are normal. If administration technique and timing are correct but IGF-1 remains unchanged, consider baseline thyroid dysfunction or growth hormone receptor resistance. Both require medical evaluation before continuing peptide research.

You cannot dose accurately without knowing concentration. Contact your supplier for the exact reconstitution details—total peptide mass and volume used. If that information is unavailable, the solution is unusable for any protocol requiring precise dosing. Pre-mixed peptides should always include concentration labeling (e.g., '2,500mcg/ml' or '2.5mg/ml') directly on the vial. Using peptides with unknown concentration introduces uncontrolled dosing variability that invalidates research outcomes entirely. Real Peptides provides exact specifications with every peptide order, eliminating this ambiguity for researchers working with compounds like BPC-157 or Ipamorelin.

Administer P21 during periods of active cognitive engagement, not passive rest. The peptide amplifies learning-induced plasticity. It doesn't create plasticity in the absence of neural activity. Studies using environmental enrichment paradigms showed that animals receiving P21 in enriched environments (novel objects, spatial navigation tasks, social interaction) demonstrated 3.2× greater dendritic spine density increases compared to animals receiving P21 in standard housing. The CREB activation pathway P21 enhances is stimulus-dependent. Calcium influx from synaptic activity triggers the kinase cascades that P21 amplifies. Without that activity, CREB phosphorylation remains at baseline despite peptide presence.

P21 costs 60–75% less per treatment course than Cerebrolysin. A 30-day research supply of P21 at 1000mcg daily runs $80–120; equivalent-duration Cerebrolysin at 30mL daily costs $300–500 depending on sourcing. For pilot studies or academic labs operating under grant constraints, P21's lower cost per subject allows larger sample sizes. But only if the research question aligns with BDNF-mediated mechanisms rather than multi-pathway neuroprotection.

If the exposure was brief (less than 24 hours), the peptide may retain 85–90% potency, but longer exposures cause cumulative degradation. Oxidation of the tryptophan residue at position 4 and deamidation of asparagine are the primary degradation pathways, both of which reduce ghrelin receptor binding affinity. Temperature-abused peptides produce inconsistent GH responses in experimental models, making dose-response data unreliable. For critical studies, discard any vial that experienced temperature excursions above 0°C for more than 48 hours. There is no way to visually confirm potency loss. Only functional assays or HPLC re-analysis can detect degradation.

Yes, but you'll only get one discrete GH pulse. The GHRP-2 acetate half life ensures plasma levels drop to baseline within 90–120 minutes, so a single morning dose provides a 30–45 minute GH peak and nothing more for the next 22 hours. If your research endpoint measures acute GH response or single-pulse IGF-1 elevation, once-daily dosing suffices. If the goal is sustained anabolic signaling, fat oxidation enhancement, or multi-pulse circadian rhythm modulation, once-daily administration underperforms two to three daily doses by a measurable margin.

Discard it and request a replacement. Temperature excursions above 8°C during shipping cause irreversible tertiary structure changes in lyophilized GHRP-2 that neither visual inspection nor home testing can detect—the powder looks identical but receptor binding affinity drops by 30–60%. Reputable peptide suppliers ship with gel ice packs and temperature indicators specifically to prevent this. If your shipment arrives warm or the indicator shows red/compromised, the peptide is no longer research-grade regardless of what the supplier claims. Real Peptides uses cold-chain logistics with 48-hour delivery windows to prevent temperature compromise during transit.

Plan for at least two separate reconstitution events to avoid potency drift beyond acceptable limits. Even with acetate stabilization, 91–94% retention at 28 days means approximately 6–8% degradation. Compounding over 12 weeks pushes cumulative loss into the 15–20% range, which introduces a time-dependent dose reduction that confounds interpretation. Reconstitute fresh stock at weeks 0, 4, and 8, and discard any remaining solution rather than extending use. Alternatively, consider a peptide with superior long-term stability like Ipamorelin, which maintains 88–91% potency over the same interval and avoids the dual-receptor complexity if your protocol is focused exclusively on GH-mediated pathways.

Verify the reconstitution protocol and storage conditions first. Once reconstituted with bacteriostatic water, adamantyl-modified peptides must be stored at 2–8°C and used within 28 days—any temperature excursion above 10°C causes partial denaturation that reduces BBB permeability without visibly altering the solution. If storage is confirmed correct, assess the administration route: subcutaneous administration in the dorsal neck or interscapular region provides more consistent lymphatic uptake than abdominal injection sites. Finally, confirm dose escalation—pilot studies should start at 1.0 mg/kg to establish whether a response occurs before increasing to 2.0 mg/kg, as individual variability in peptidase expression can affect systemic exposure.

Reverse the administration timing. GHRP-2 administered too close to sleep onset can increase arousal in some individuals due to transient cortisol or prolactin elevation. Both can occur as secondary responses to GH secretagogue stimulation. Shift administration to early morning (fasted, upon waking) or mid-afternoon (3–4 hours post-lunch, 4+ hours before sleep). If sleep disruption persists, reduce dose by 30–50% and re-titrate slowly. Additionally, evaluate baseline cortisol rhythm via salivary cortisol testing. Individuals with pre-existing HPA axis dysfunction may experience paradoxical sleep disruption from peptides that alter neuroendocrine signaling.

This reflects differences in model systems, administration routes, and endpoint measurements. Not incorrect dosing. Rodent studies dose per kilogram body weight; in vitro studies dose per milliliter culture medium; human observational studies often report total course doses rather than per-injection amounts. Cross-species dose translation requires allometric scaling (multiplying rodent mg/kg doses by approximately 0.16 to estimate human equivalent doses). When designing a protocol, identify studies using your specific model (in vitro chondrocyte culture, in vivo osteoarthritis model, etc.) and match their methodology rather than averaging across unrelated study types.

Use the largest gauge beveled needle available—preferably 18 or 20 gauge—and execute the wall-directed reconstitution technique with extreme precision. Direct the fluid stream against the vial wall at the lowest velocity possible, achieved by pressing the syringe plunger slowly over 15–20 seconds rather than a rapid 3-second injection. The larger internal diameter partially compensates for the shear forces created by the beveled tip, and the extended injection time allows the lyophilised FOXO4-DRI to dissolve through diffusion rather than mechanical disruption. Accept that this compromise increases foam formation risk—if visible foam appears, allow the vial to rest undisturbed at room temperature for 10 minutes before drawing the first dose, giving the foam time to dissipate and the peptide structure time to stabilize.

The peptide's biological half-life won't change, but potency might. Reconstituted GHRP-2 in bacteriostatic water remains stable at 2–8°C for 28 days, but room temperature (20–25°C) accelerates peptide bond hydrolysis and bacterial growth in non-sterile environments. A two-hour excursion likely causes negligible degradation. Peptides don't denature instantly. But repeated temperature cycling across days reduces effective dose. The GHRP-2 acetate half life in vivo is unaffected; what changes is how much active peptide you're injecting. Store reconstituted vials refrigerated between doses.

Discard the vial. Lyophilized peptides tolerate brief (under 2 hours) excursions to 25°C, but anything longer or warmer triggers irreversible aggregation. The peptide may still dissolve and appear normal, but biological activity degrades unpredictably. Some batches lose 20% activity, others lose 80%. There's no reliable way to assess potency loss without running the full study and discovering halfway through that your data doesn't replicate. Real Peptides uses insulated packaging with gel packs for this exact reason, but if a package sits on a loading dock in summer heat, request a replacement rather than gamble on compromised product.

Request an extended certificate of analysis from Real Peptides that includes synthesis method (solid-phase peptide synthesis), purification technique (reverse-phase HPLC), purity verification (HPLC chromatogram with peak integration), sequence confirmation (mass spectrometry and amino-acid analysis reports), endotoxin testing (LAL assay results with EU/mg quantification), and storage recommendations. Many journals now require peptide source disclosure with catalog numbers and lot-specific quality documentation to enable protocol replication. Archive CoA documents with raw data files because reviewers increasingly request substrate specifications during peer review.

Dihexa is the superior choice for systemic administration studies. Its lipophilic structure allows passive diffusion across endothelial tight junctions, achieving measurable hippocampal and cortical concentrations within 30–60 minutes of subcutaneous injection. P21 requires intranasal delivery to bypass the blood-brain barrier via olfactory pathways, or substantially higher systemic doses (often 5–10× higher than Dihexa on a mg/kg basis) to achieve comparable CNS exposure through less efficient transport mechanisms. If your research design cannot accommodate intranasal delivery or frequent high-dose injections, Dihexa's pharmacokinetic profile is operationally easier to work with.

Discard the vial. It is no longer viable. Freezing aqueous peptide solutions causes ice crystal formation that physically disrupts peptide structure through mechanical shearing. Even if the solution appears clear after thawing, the peptide has undergone irreversible aggregation and conformational changes that eliminate biological activity. This is not a recoverable error. The visual clarity of the thawed solution is misleading. Aggregated peptides remain in solution and do not precipitate immediately, but they no longer bind to growth hormone secretagogue receptors with the same affinity or efficacy.